These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 26842912)

  • 41. Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors.
    Kumar SR; Kim DY; Henry CJ; Bryan JN; Robinson KL; Eaton AM
    Vet Comp Oncol; 2017 Dec; 15(4):1527-1536. PubMed ID: 28111882
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity.
    Mandai M; Hamanishi J; Abiko K; Matsumura N; Baba T; Konishi I
    Clin Cancer Res; 2016 May; 22(10):2329-34. PubMed ID: 27016309
    [TBL] [Abstract][Full Text] [Related]  

  • 43. IL-12 regulates B7-H1 expression in ovarian cancer-associated macrophages by effects on NF-κB signalling.
    Xiong HY; Ma TT; Wu BT; Lin Y; Tu ZG
    Asian Pac J Cancer Prev; 2014; 15(14):5767-72. PubMed ID: 25081699
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bladder cancer cells induce immunosuppression of T cells by supporting PD-L1 expression in tumour macrophages partially through interleukin 10.
    Wang X; Ni S; Chen Q; Ma L; Jiao Z; Wang C; Jia G
    Cell Biol Int; 2017 Feb; 41(2):177-186. PubMed ID: 27987237
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas.
    Koelblinger P; Emberger M; Drach M; Cheng PF; Lang R; Levesque MP; Bauer JW; Dummer R
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):667-675. PubMed ID: 30357969
    [TBL] [Abstract][Full Text] [Related]  

  • 46. M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling.
    Zong Z; Zou J; Mao R; Ma C; Li N; Wang J; Wang X; Zhou H; Zhang L; Shi Y
    Front Immunol; 2019; 10():1643. PubMed ID: 31379842
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Propranolol reduces IFN-γ driven PD-L1 immunosuppression and improves anti-tumour immunity in ovarian cancer.
    Falcinelli M; Al-Hity G; Baron S; Mampay M; Allen MC; Samuels M; Jones W; Cilibrasi C; Flaherty RL; Giamas G; Thaker PH; Flint MS
    Brain Behav Immun; 2023 May; 110():1-12. PubMed ID: 36796704
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PD-L1.
    Kythreotou A; Siddique A; Mauri FA; Bower M; Pinato DJ
    J Clin Pathol; 2018 Mar; 71(3):189-194. PubMed ID: 29097600
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.
    Qorraj M; Bruns H; Böttcher M; Weigand L; Saul D; Mackensen A; Jitschin R; Mougiakakos D
    Leukemia; 2017 Feb; 31(2):470-478. PubMed ID: 27479178
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of an in vitro assay for screening programmed death receptor-1/programmed cell death ligand 1 monoclonal antibody therapy in dogs.
    Mizuno T; Kato M; Tsukui T; Igase M
    Vet Immunol Immunopathol; 2024 Aug; 274():110792. PubMed ID: 38878679
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma.
    Kim J; Kim TJ; Chae S; Ha H; Park Y; Park S; Yoon CJ; Lim SA; Lee H; Kim J; Kim J; Im K; Lee K; Kim J; Kim D; Lee E; Shin MH; Park SI; Rhee I; Jung K; Lee J; Lee KH; Hwang D; Lee KM
    Mol Cancer; 2024 Feb; 23(1):45. PubMed ID: 38424542
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IL-27 induces the expression of IDO and PD-L1 in human cancer cells.
    Carbotti G; Barisione G; Airoldi I; Mezzanzanica D; Bagnoli M; Ferrero S; Petretto A; Fabbi M; Ferrini S
    Oncotarget; 2015 Dec; 6(41):43267-80. PubMed ID: 26657115
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice.
    Rangan L; Galaine J; Boidot R; Hamieh M; Dosset M; Francoual J; Beziaud L; Pallandre JR; Lauret Marie Joseph E; Asgarova A; Borg C; Al Saati T; Godet Y; Latouche JB; Valmary-Degano S; Adotévi O
    Oncotarget; 2017 Jul; 8(30):48959-48971. PubMed ID: 28430664
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1.
    Roux C; Jafari SM; Shinde R; Duncan G; Cescon DW; Silvester J; Chu MF; Hodgson K; Berger T; Wakeham A; Palomero L; Garcia-Valero M; Pujana MA; Mak TW; McGaha TL; Cappello P; Gorrini C
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4326-4335. PubMed ID: 30770442
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Regulatory Mechanisms of PD-L1 Expression and Its Role in Immune Evasion].
    Kataoka K
    Gan To Kagaku Ryoho; 2017 Nov; 44(11):967-971. PubMed ID: 29138368
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.
    Gordon SR; Maute RL; Dulken BW; Hutter G; George BM; McCracken MN; Gupta R; Tsai JM; Sinha R; Corey D; Ring AM; Connolly AJ; Weissman IL
    Nature; 2017 May; 545(7655):495-499. PubMed ID: 28514441
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.
    Hogg SJ; Vervoort SJ; Deswal S; Ott CJ; Li J; Cluse LA; Beavis PA; Darcy PK; Martin BP; Spencer A; Traunbauer AK; Sadovnik I; Bauer K; Valent P; Bradner JE; Zuber J; Shortt J; Johnstone RW
    Cell Rep; 2017 Feb; 18(9):2162-2174. PubMed ID: 28249162
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours.
    Ariyarathna H; Thomson NA; Aberdein D; Perrott MR; Munday JS
    Vet Immunol Immunopathol; 2020 Dec; 230():110142. PubMed ID: 33129194
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway.
    Wang TT; Zhao YL; Peng LS; Chen N; Chen W; Lv YP; Mao FY; Zhang JY; Cheng P; Teng YS; Fu XL; Yu PW; Guo G; Luo P; Zhuang Y; Zou QM
    Gut; 2017 Nov; 66(11):1900-1911. PubMed ID: 28274999
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development and characterization of mouse anti-canine PD-L1 monoclonal antibodies and their expression in canine tumors by immunohistochemistry
    Sirivisoot S; Boonkrai C; Wongtangprasert T; Phakham T; Muanwein P; Pisitkun T; Sawangmake C; Radtanakatikanon A; Rungsipipat A
    Vet Q; 2023 Dec; 43(1):1-9. PubMed ID: 37477617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.